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Objectives This study investigated the effect of catheter-based renal sympathetic denervation (RD) on left ventricular hyper-
trophy (LVH) and systolic and diastolic function in patients with resistant hypertension.
Background LVH and diastolic dysfunction are associated with elevated sympathetic activity and increased morbidity and
mortality. The effect of RD on LVH and LV function is unclear.
Methods Forty-six patients underwent bilateral RD, and 18 patients served as controls. Transthoracic echocardiography
was performed at baseline, and after 1 month and 6 months.
Results Besides reduction of systolic and diastolic blood pressure (22.5/7.2 mm Hg at 1 month and 27.8/8.8 mm Hg
at 6 months, p  0.001 at each time point), RD significantly reduced mean interventricular septum thickness from
14.1  1.9 mm to 13.4  2.1 mm and 12.5  1.4 mm (p  0.007), and LV mass index from 53.9  15.6 g/m2.7
(112.4  33.9 g/m2) to 47.0  14.2 g/m2.7 (103.6  30.5 g/m2) and 44.7  14.9 g/m2.7 (94.9  29.8 g/m2)
(p  0.001) at 1 month and 6 months, respectively. The mitral valve lateral E/E= decreased after RD from 9.9  4.0
to 7.9  2.2 at 1 month and 7.4  2.7 at 6 months (p  0.001), indicating reduction of LV filling pressures. Isovolu-
mic relaxation time shortened (baseline 109.1  21.7 ms vs. 85.6  24.4 ms at 6 months, p  0.006), whereas
ejection fraction significantly increased after RD (baseline: 63.1  8.1% vs. 70.1  11.5% at 6 months, p  0.001).
No significant changes were obtained in control patients.
Conclusions Besides the known effect on blood pressure, our study showed for the first time that RD significantly reduces LV
mass and improves diastolic function, which might have important prognostic implications in patients with resis-
tant hypertension at high cardiovascular risk. (J Am Coll Cardiol 2012;59:901–9) © 2012 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.034t
p
eHypertension is a risk factor for coronary artery disease,
myocardial infarction, and stroke. Patients with therapy-
refractory hypertension are at particular risk for cardiovascular
events. Even before clinical events occur, hypertension induces
changes of the heart, including left ventricular hypertrophy
(LVH) and cardiac fibrosis (1). These structural alterations are
associated with functional impairment of the left ventricle
(LV), i.e., abnormal diastolic relaxation and increased diastolic
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2011, accepted November 14, 2011.filling pressures. Notably, diastolic dysfunction may already be
present in hypertensive patients with normal LV mass (2,3).
See page 910
LVH and diastolic dysfunction have been linked to
cardiovascular morbidity and mortality (4,5). Regression of
LVH was shown to improve cardiovascular outcome inde-
pendently of other risk factors, and thus has been suggested
as an intermediate endpoint (6,7). However, despite a
similar reduction of blood pressure (BP), efficacy on LVH
regression varies among different antihypertensive drugs (8).
The cause of resistant arterial hypertension is multifac-
orial. Chronic activation of the sympathetic nervous system
lays a central role in the pathophysiology of both BP
levation and development of LVH (9–11). Reduction of
enal sympathetic afferent and efferent activity by percuta-
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cular radiofrequency ablation of
the renal sympathetic nerves ef-
fectively decreased systolic blood
pressure (SBP) and diastolic blood
pressure (DBP) in patients with
resistant hypertension (12,13).
However, the impact of renal sym-
pathetic denervation (RD) on
LVH is unclear. Therefore, we
evaluated whether this new thera-
peutic approach has a positive ef-
fect on LVH as measured by hy-
pertensive end-organ damage and
on diastolic dysfunction.
Methods
The study was approved by the
local ethics committees in accor-
dance with the Declaration of
Helsinki. Patients were treated between October 2009 and
January 2011, with subsequent follow-up for 6 months. All
patients provided written informed consent.
Study subjects. Eligible patients were older than 18 years and
had an office BP of 160 mm Hg (150 mm Hg for type 2
iabetes patients) or more, despite treatment with at least 3
ntihypertensive drugs (including a diuretic), with no changes
n medication for a minimum of 3 months before enrollment.
o exclude white coat hypertension, 24-h BP recordings and
ome BP protocols were consulted in addition to office BP
easurements at the hospital before enrollment. Patients with
econdary causes of hypertension were excluded. Further exclu-
ion criteria have been reported previously (13,14). Forty-six
atients underwent renal denervation, and 18 patients were in the
ontrol group. In all patients, the same inclusion/exclusion criteria
ere applied as part or extension of the randomized controlled
ymplicity HTN-2 (Renal Denervation in Patients With Uncon-
rolled Hypertension) protocol (NCT00888433) (13).
P measurements. Before BP measurements, the adher-
nce of the patients to their antihypertensive medications
as ensured. BP and heart rate were recorded after 10 min
f supine rest using an automatic oscillometric monitor
Omron HEM-705, Omron Healthcare, Vernon Hills,
llinois) on the brachial artery. BP was measured on the
ame side throughout the study. Averages of triplicate
easurements with 1-min intervals were used for analysis.
ransthoracic echocardiography. Transthoracic echocar-
iography was performed at baseline, 1-month, and
-month follow-up using a Philips iE 33 ultrasound system
Amsterdam, the Netherlands) equipped with a multifre-
uency transducer and tissue Doppler imaging software
ccording to the Guidelines of the American Society of
chocardiography (15). Data were analyzed and interpreted
y 2 experienced echocardiographers blinded to treatment
Abbreviations
and Acronyms
BMI  body mass index
BP  blood pressure
DBP  diastolic blood
pressure
IVSTd  end-diastolic
interventricular septum
thickness
LA  left atrium
LV  left ventricle
LVH  left ventricular
hypertrophy
RD  renal sympathetic
denervation
RWT  relative wall
thickness
SBP  systolic blood
pressuretatus and sequence of the images. SDiastolic functional parameters were recorded following
ecent recommendations of the American Society of Echo-
ardiography (16). The LV mass was calculated from LV
inear dimensions using the Devereux formula (15,17). LV
ass was indexed to the body surface area and to the height
o the 2.7 power (15,18), as indicated. LVH was considered
resent when the LV mass exceeded 115 g/m2 and 48
/m2.7, respectively, for men and 95 g/m2 and 44 g/m2.7,
respectively, for women (15). Relative wall thickness
(RWT) was calculated by end-diastolic interventricular
septum thickness (IVSTd)  end-diastolic posterior wall
thickness/end-diastolic internal dimension, with RWT
0.42, indicating concentric LV remodeling/hypertrophy
(15,19).
RD procedure. Renal angiograms were performed via
femoral access to confirm anatomic eligibility. In the same
session, RD was performed using the Symplicity or Flex
catheter (by Ardian, Palo Alto, California), as previously
reported (14). Up to 6 ablations at 8 W for 2 min each were
performed in both renal arteries.
Statistical analysis. Data are presented as mean  SD.
Differences in the mean values were compared using a
2-tailed t test for continuous variables and Fisher-Yates
testing for nominal variables. Changes of all parameters
with multiple measurements, including p for statistical
trend, were analyzed from baseline to 1 and 6 months by
2-factor analysis of variance for repeated measurements.
The Scheffé correction algorithm was used to compute post
hoc comparisons of significant values. A comparison be-
tween linear trends in treatment and control groups was
performed using the group square linear trend interaction
test. For N-terminal pro–B-type natriuretic peptide values
with a highly skewed distribution, statistical significance
was calculated using the Wilcoxon-Mann-Whitney test. A
p value 0.05 was considered statistically significant. All
statistical analyses were performed with SPSS statistical
software (version 12.0, SPSS Inc., Chicago, Illinois).
Results
Patient characteristics. Sixty-four patients with arterial
hypertension refractory to medical therapy were included in
the study. Forty-six patients were treated with RD, 18
patients served as controls. The mean age in the treatment
group was 63  10.1 years; males were a majority of 67%
Table 1). The mean body mass index (BMI) was above
ormal with 28.6  3.3 kg/m2, and 27.4% of patients had
BMI 30 kg/m2. On average, patients were taking 4.7
ifferent antihypertensive drugs. The most frequently used
ubstance groups were beta-blockers (98%), ACE inhibitors
r AT1-receptor blockers (98%), and calcium channel
lockers (87%). All patients were on diuretic agents. The
atient demographic and clinical characteristics did not
iffer between the RD and control groups (Table 1).
P control by RD. At baseline, the mean sitting office
BP/DBP in the treatment group (180.7  18.3/95.8 
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March 6, 2012:901–9 Renal Denervation Reduces LV Hypertrophy10.1 mm Hg) and the control group (184.5  22.1/98.2 
13.6 mm Hg, p  0.503/0.496) were similar (Table 2, Figs. 1B
and 1C). RD significantly reduced BP at 1 month (158.2 
17.6/88.6  10.9 mm Hg, p  0.001/0.001) and 6 months
(152.9  22.4/87.0  12.9 mm Hg, p  0.001/0.014),
whereas BP remained unchanged in the control group
(Table 2, Fig. 1). In the control group, the number and
dosage of antihypertensive drugs remained constant during
follow-up. After RD, the number of antihypertensive drugs
could be reduced in 7 patients (15%), resulting in an average
of 4.5 1.6 antihypertensive drugs at 6 months versus 4.7 1.5
at baseline (p  0.402). Additionally, in a further 8 patients
(17%), the dosage of at least 1 antihypertensive drug was
reduced after RD.
Regression of LVH. The LV mass index decreased contin-
uously in the RD group, from 53.9  15.6 g/m2.7 (112.4 
33.9 g/m2) at baseline to 47.0  14.2 g/m2.7 (103.6  30.5
/m2) at 1 month (p  0.001/0.01) and 44.7  14.9 g/m2.7
(94.9 29.8 g/m2) at 6 months (p 0.001/0.001 vs. baseline,
p for trend 0.001/0.004), respectively, whereas LV mass
lightly increased in the control group, from 55.7  15.3
/m2.7 (114.8  41.6 g/m2) at baseline to 58.6  16.1 g/m2.7
(118.7  30.1 g/m2) at 6 months (p  0.007/0.009 vs. RD)
(Table 2, Fig. 2A). In the RD group, 63% and 33% had LVH
(indexed to height2.7) at baseline and after 6 months, respec-
ively. Consistently, after RD, but not in control patients, there
as a significant reduction of the interventricular septum
hickness (RD: 14.1 1.9 mm at baseline vs. 13.4 2.1 mm
t 1 month, p  0.005, vs. 12.5  1.4 mm at 6 months, p 
.009, p for trend  0.007) (Fig. 2B).
The effect of RD on LV mass regression correlated with
Patient Characteristics at BaselineTable 1 Patient Characteristics at Baseline
Renal Denervation
(n  46)
Control
(n  18) p Value
Age, yrs 63.1 10.2 63.0 15.3 0.977
Male 31 (67%) 11 (61%) 0.771
BMI, kg/m2 28.6 3.4 28.1 3.8 0.595
Coronary artery disease 20 (44%) 7 (39%) 0.785
Atrial fibrillation 7 (15%) 2 (11%) 1.000
Stroke 8 (17%) 4 (22%) 0.726
Type 2 diabetes 21 (46%) 7 (39%) 0.781
Hypercholesterolaemia 32 (70%) 10 (56%) 0.382
Smoking 14 (30%) 3 (17%) 0.086
Number of antihypertensive drugs 4.7 0.5 4.8 2.5 0.979
Patients receiving (drug class)
ACE inhibitors/ARBs 45 (98%) 18 (100%) 1.000
Direct renin inhibitors 17 (37%) 5 (28%) 0.770
Beta-blockers 45 (98%) 16 (89%) 0.189
Calcium-channel blockers 40 (87%) 13 (72%) 0.267
Diuretics 46 (100%) 18 (100%) 1.000
Oral sympatholytics 23 (50%) 7 (39%) 0.579
Values are mean  SD or n (%). Statistical differences between groups, where applicable, are
indicated in the far-right column.
ACE  angiotensin converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
index (kg/m2).the degree of myocardial hypertrophy at baseline and wasmost evident in patients with LVH at baseline. Although in
patients without LVH (indexed to height2.7), no significant
hange of LV mass after RD occurred, in the subgroup with
VH at baseline (n  29, 63%), RD markedly reduced LV
ass index by 8.0  11.9 g/m2.7 (p  0.08 vs. no LVH,
 0.06 vs. baseline) and 13.5  10.4 g/m2.7 (p  0.009
vs. no LVH, p  0.004 vs. baseline) after 1 month and 6
months, respectively (Figs. 2C and 2D). Eccentric LVH,
i.e., RWT 0.42 was evident in only 2 patients before RD
and was not detected 6 months post-intervention. Consis-
tently, LV mass regression by RD was predominantly due to
a marked decrease of LV wall thickness, rather than a
reduction of end-diastolic LV internal dimension (Table 2).
In patients without LVH, 53% and 41% exhibited concen-
tric LV remodeling at baseline and 6 months after RD,
respectively.
Improvement of systolic function. The LV end-systolic
volume was significantly reduced by RD (32.8  15.6 ml at
baseline, to 27.7  12.8 ml at 1 month, p  0.001, and 25.6 
2.5 ml at 6 months, p 0.001 vs. baseline, p for trend0.001,
 0.03 vs. control). This was associated with a significant
ncrease of the LV ejection fraction in the RD group (LV ejection
raction: 63.1 8.1% at baseline to 69.1 7.5% at 1 month, p
0.001, and 70.1 11.5% at 6 months, p 0.001, p for trend
0.001) (Table 2). Conversely, no reduction of LV end-systolic
volume and no improvement of LV ejection fraction were ob-
tained in control patients (Table 2).
Improvement of diastolic function. In addition, regres-
sion of LV mass in patients who underwent RD was
accompanied by an improvement of diastolic functional
parameters, whereas in control patients, a trend towards
progression of diastolic dysfunction was observed (Table 2).
The mitral E-wave deceleration time shortened steadily
after RD, from 227.2 66.5 ms at baseline to 211.3 57.6
s at 1 month and 185.2 67.1 ms at 6 months (p 0.013
s. baseline, p for trend  0.003). Consistent with an
mprovement of diastolic LV relaxation, RD significantly
educed the isovolumic relaxation time from 109.1  21.7
s at baseline to 93.0  22.4 ms at 1 month (p  0.001 vs.
aseline) and 85.6  24.4 ms at 6 months (p  0.006 vs.
aseline, p for trend 0.002, p  0.008 vs. control).
Tissue Doppler imaging revealed a significant increase of
he diastolic relaxation velocity of the lateral mitral annulus
ollowing RD (Table 2). Furthermore, the ratio of mitral
nflow velocity to annular relaxation velocity (lateral E/E=),
marker of LV diastolic filling pressure, significantly
ecreased as early as 1 month after RD (9.9  4.0 at
aseline vs. 7.9 2.2 at 1 month, p 0.001) and continued
o decline throughout the 6-month follow-up (7.4  2.7,
 0.001 vs. baseline, p for trend 0.001, p  0.001 vs.
control) (Fig. 3A). The percentage of patients with normal
LV filling pressures, i.e., an E/E= ratio 8, increased from
39% at baseline to 58% at 1 month and 68% at 6 months
post-RD, whereas the percentage of patients with increased
LV filling pressures based on the E/E= ratio (E/E= ratio
Blood Pressure, Echocardiographic, and Laboratory Parameters in RD and Control Patients at Baseline, 1 Month, and 6 MonthsTable 2 Blood Pressure, Echocardiographic, and Laboratory Parameters in RD and Control Patients at Baseline, 1 Month, and 6 Months
Renal Denervation (n46) Control (n18)
RD vs. Control
Differential EfficacyBaseline 1 Month 6 Months
p for
Trend Baseline 1 Month 6 Months
p for
Trend
Basic hemodynamic parameters
Resting SBP (mm Hg) 180.7 18.3 158.2 17.6 152.9 22.4 0.001 184.5 22.1 181.6 26.3 182.8 24.6 0.864 0.039
Resting DBP (mm Hg) 95.8 10.1 88.6 10,9 87.0 12.9 0.001 98.2 13.6 98.0 12.7 99.8 16.5 0.792 0.041
Peripheral PP (mm Hg) 84.3 14.9 69.6 13.6 65.2 17.0 0.001 86.2 19.1 83.6 18.2 83.0 17.0 0.798 0.041
Heart rate at rest (beats/min) 66.5 12.2 61.9 9.5 60.9 16.3 0.003 66.3 16.5 66.4 11.9 64.3 14.0 0.752 0.047
Echocardiographic parameters
Left atrial diameter (mm) 45.2 6.1 43.0 5.3 42.5 6.0 0.001 43.7 5.3 44.5 4.2 46.0 5.5 0.495 0.021
IVSTd (mm) 14.1 1.9 13.4 2.1 12.5 1.4 0.007 14.2 1.9 14.2 1.6 14.2 1.9 0.815 0.032
LVIDd (mm) 46.5 5.4 47.7 4.7 47.3 6.0 0.232 44.5 8.5 45.3 6.8 46.4 7.6 0.417 0.097
PWTd (mm) 11.1 2.7 9.9 3.3 9.3 2.8 0.001 12.0 3.4 11.7 2.1 11.3 3.0 0.676 0.019
LV end-diastolic volume (ml) 87.0 28.5 87.1 28.7 84.6 45.4 0.635 85.9 36.5 86.0 40.7 84.0 37.8 0.966 0.783
LV end-systolic volume (ml) 32.8 16.1 27.7 13.5 25.6 12.5 0.001 31.1 18.2 30.6 16.1 31.8 19.5 0.811 0.015
LVEF Simpson (%) 63.1 8.1 69.1 7.5 70.1 11.5 0.001 64.3 7.2 63.9 8.9 62.9 8.1 0.467 0.048
LV mass/body surface area (g/m2) 112.4 33.9 103.6 30.5 94.9 29.8 0.004 114.8 41.6 115.3 23.3 118.7 30.1 0.634 0.004
LV mass/height2.7 (g/m2.7) 53.9 15.6 47.0 14.2 44.7 14.9 0.001 55.7 15.3 55.8 17.4 58.6 16.1 0.369 0.001
Mitral valve E Vmax (cm/s) 74.2 21.0 70.3 17.0 74.3 24.4 0.708 74.7 31.4 74.2 26.4 76.5 22.5 0.892 0.987
Mitral valve A Vmax (cm/s) 85.8 23.7 79.7 17.6 79.6 21.7 0.028 78.6 50.9 83.6 27.6 85.6 28.8 0.609 0.048
Mitral valve E/A ratio 0.89 0.29 0.90 0.27 1.12 0.88 0.183 0.88 0.21 0.87 0.25 0.90 0.25 0.878 0.387
Mitral valve E deceleration time (ms) 227.2 66.5 211.3 57.6 185.2 67.1 0.003 236.0 115.0 253.9 70.4 233.4 89.0 0.745 0.008
Mitral valve lateral E’ (cm/s) 8.1 2.8 9.5 2.4 9.9 2.7 0.001 6.6 2.5 6.1 2.5 6.3 1.7 0.541 0.023
Mitral valve lateral E/E’ 9.9 4.0 7.9 2.2 7.4 2.7 0.001 10.9 3.0 12.3 4.2 12.1 3.8 0.495 0.001
Isovolumic relaxation time (ms) 109.1 21.7 93.0 22.4 85.6 24,4 0.002 119.4 26.3 111.8 14.0 111.6 40.7 0.615 0.001
TAPSE (mm) 22.8 6.1 24.9 5.8 25.75 6.8 0.009 21.9 8.9 22.6 11.9 22.2 7.6 0.949 0.063
Laboratory tests
Serum creatinine (mg/dl) 0.98 0.3 1.01 0.4 0.93 0.7 0.519 0.98 0.50 0.99 0.63 0.90 0.51 0.741 0.891
eGFR (ml/min/1.73 m2) 83.5 27.8 80.1 28.5 84.7 31.2 0.592 80.5 29.3 80.9 36.5 89.5 28.8 0.343 0.476
NT-pro-BNP (ng/l) 760 1,451 564 1,072 492 1,078 0.274 1,115 1,700 1,101 1,491 1,022 1,798 0.876 0.583
Values are mean SD. Differential efficacy between RD and control group was tested using the group square linear trend interaction test.
DBP  diastolic blood pressure; eGFR  estimated glomerular filtration rate; IVSTd  end-diastolic interventricular septum thickness; LVEF  left ventricular ejection fraction; LVIDd  end-diastolic left ventricular internal dimension; PP  pulse pressure; PWTd  left
ventricular end-diastolic posterior wall thickness; SBP  systolic blood pressure; TAPSE  systolic lateral tricuspid annulus excursion.
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March 6, 2012:901–9 Renal Denervation Reduces LV Hypertrophy12) declined from 29% at baseline to 4% after 1 month
and 6 months, respectively (16).
A decrease of the E/E’ ratio after RD, indicating reduc-
tion of LV filling pressures, was particularly pronounced in
patients with elevated baseline values above the median of
8.8. In this subgroup, E/E= decreased by 4.2  2.9 at 1
month (p  0.001) and 4.4  3.1 at 6 months (p 
0.013) post-RD (Fig. 3B). Moreover, reduction of the E/E=
ratio was more marked in the presence of LVH. Although
in patients without LVH (indexed to height2.7), no signif-
icant change of the E/E= ratio 6 months after RD occurred
(0.17  1.7; p  0.42 vs. baseline), in the subgroup with
LVH at baseline, RD reduced the E/E= ratio by3.0 3.2
(p  0.032 vs. no LVH, p  0.012 vs. baseline).
Consistent with a pronounced reduction in LV filling
pressures by RD, left atrial (LA) size significantly decreased
after RD, whereas in the control group, LA size signifi-
cantly increased during follow-up (Table 2). At baseline,
55% in the RD group and 45% in the control group had
increased LA diameters 44 mm. This percentage declined
to 35% 6 months after RD, whereas in control patients, the
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for SBP (B), p  0.001 for DBP (C), and p  0.001 for pulse pressure (D). Valuepercentage remained statistically unchanged at 46%.RD-induced LVH regression not exclusively associated
with BP reduction. To evaluate a potential impact of the
efficacy of BP reduction by RD on regression of LVH and
improvement of diastolic function, patients were divided
into tertiles according to the SBP decrease after 1 month
and 6 months, respectively. As demonstrated in Figure 4,
both regression of LV mass and reduction of the E/E= ratio
were most pronounced in patients with the most marked
SBP decrease.
Six patients (13%) showed 10 mm Hg BP-lowering
response 6 months after RD, previously defined as “nonre-
sponders” (12). Notably, in 5 of these patients, we still
obtained a marked reduction of the LV mass index by8.8 6.6
g/m2.7 and in 4 patients a decrease of the E/E= ratio by 4.9 
5.2, indicating BP-independent effects of RD on LVH and
diastolic dysfunction.
Discussion
Although for many years, reduction of peripheral BP per se
was the target in the treatment of patients with arterial
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Renal Denervation Reduces LV Hypertrophy March 6, 2012:901–9BP control may differentially affect outcome (20,21). Crit-
ically, it has been discussed that the lowering of peripheral
BP rather represents a surrogate endpoint that does not
automatically lead to a parallel decrease in cardiovascular
morbidity and mortality (7). Conversely, intermediate end-
points such as LVH were shown to be reliably linked to
cardiovascular prognosis (22,23). LVH is an indicator of
end-organ damage in arterial hypertension. The presence of
LVH is associated with an increased rate of cardiovascular
events and death independent of other cardiovascular risk
factors and, notably, independent of BP values (5,24,27).
Consistently, LVH regression was accompanied by favorable
outcome (22,23). In this respect, it is of importance that in the
present study, in addition to the BP-lowering effect, we were
able to demonstrate early and marked reduction of LV mass
and improvement of diastolic dysfunction by RD in patients
with therapy-resistant hypertension.
Chronic activation of the sympathetic nervous system is
involved in the development and maintenance of arterial
hypertension (9,28). Moreover, sympathetic overactivity is a
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(n  29). LVMI  left ventricular mass index.key component of the signaling pathways altered inhypertension-related cardiac remodeling (10,11). However,
in the LIFE (Losartan Intervention For Endpoint reduction
in Hypertension) study, antihypertensive treatment with
atenolol-based therapy resulted in less LVH regression than
a losartan-based strategy (29). This clinical observation was
further supported by a meta-analysis demonstrating that
beta-blockers induced significantly less LVH regression
compared with various other antihypertensive drugs, espe-
cially blockers of the rennin-angiotensin system (8). The
diminished efficacy of beta-blockers on LVH reduction
might reside in their inability to decrease myocardial fibrosis
(30). Experimental evidence indicates that the sympathetic
nervous system mediates hypertension-induced hypertrophy
via direct stimulation of cardiomyocyte beta-adrenergic
receptors (31). Conversely, cardiac fibrosis and inflamma-
tion have been suggested to result from a self-perpetuating
circuit involving mast cell activation, stimulation of afferent
sympathetic nerves, angiotensin II production, and norepi-
nephrine release, rather than being mediated via alpha-
adrenergic receptors (32). In line with this notion, in a
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interstitial fibrosis was abolished by sympathectomy or
doxazosin but left unchanged by beta-blockade (31). These
effects were independent of BP control (31).
Catheter-based RD reduces renal sympathetic efferent
activity shown by a reduction of noradrenaline spillover
(33). Furthermore, whole-body sympathetic activation is
reduced by the ablation of afferent renal nerves, which
stimulate sympathetic outflow in the hypothalamus (9,34).
hus, in contrast to beta-blockers, RD will diminish both
eta- and alpha-receptor–mediated hyperactivity. In the
resent study, we obtained a pronounced reduction of LV
ass by 9.2 g/m2.7 (17% from baseline) after RD, indi-
ating a more pronounced effect of RD in this treatment-
esistant patient group compared with drug interventions
or uncomplicated hypertension (35). Although it is not
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(A) Mitral valve lateral (lat.) E/E= at baseline, 1 month, and 6 months in renal
sympathetic denervation (RD) and control patients. While no significant
changes could be detected in the control group, E/E= significantly decreased in
the RD group. In the treatment group, p for trend was 0.001. (B) Differential
effect of RD on E/E= reduction depended on the degree of diastolic dysfunction
at baseline. Reduction of E/E= by RD was significantly greater in those patients
with an E/E= above the median of 8.8 at baseline. Values are presented as
mean  standard error.ossible to distinguish how much of these changes wereaused by BP reduction related to RD versus sympathetic
enervation per se, consistent with animal models, LV mass
egression occurred also in 5 of 6 RD “nonresponders” (12),
upporting the notion of BP-independent effects of RD on
VH. Besides the aforementioned signaling pathways,
hese antihypertrophic effects might in part be mediated via
educed insulin concentrations after RD (14).
Both concentric and asymmetric myocardial hypertrophy
re indicators of adverse prognosis (36). IVSTd was in-
reased in all our patients, with a majority presenting
oncentric LVH (RWT 0.42) similar to previous reports
37,38). In these patients, we consistently observed regres-
ion of IVSTd and LV mass. However, we are not able to
valuate the impact of RD on eccentric hypertrophy, that is,
WT 0.42, because of the limited number of patients
ith this LV geometry in our population (15,19).
Several studies indicated a close relation between refrac-
ory hypertension and LVH, as well as LVH and diastolic
ysfunction (39,40). However, abnormalities of diastolic
unction have also been found in patients without measur-
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908 Brandt et al. JACC Vol. 59, No. 10, 2012
Renal Denervation Reduces LV Hypertrophy March 6, 2012:901–9able myocardial hypertrophy (2,3). In the present study,
besides inducing LVH regression, RD significantly im-
proved cardiac functional parameters. Renal sympathetic
nerve ablation reduced LV volumes, increased the ejection
fraction, and improved diastolic dysfunction, such as myo-
cardial relaxation and end-diastolic pressures as indicated by
left ventricular mitral valve E/E= and LA size, which have
been linked to improved prognosis in pharmaceutical inter-
ventional trials (22,23). Diastolic function is modulated by
multiple factors. Reduction of LV filling pressure and
regression of LV wall thickness will have improved diastolic
dysfunction after RD. A potential impact of RD on myo-
cardial fibrosis remains speculative. Although pressure over-
load per se affects myocardial collagen content, reduction of
sympathetic and renin-angiotensin-aldosterone system ac-
tivity, known to occur after RD, might also facilitate
regression of myocardial fibrosis (41).
Study limitations. Given the lack of other therapeutic
options for resistant arterial hypertension, we are not able to
compare the effects of RD with other treatment strategies.
The cohort in our study was comparatively small with a
follow-up of 6 months, not allowing analysis of clinical
outcome. Future results of this trial with longer follow-up
and a larger cohort of treated patients will therefore be of
interest.
Conclusions
RD offers a novel and safe catheter-based approach for
selective reduction of renal sympathetic drive. We demon-
strate for the first time to our knowledge that selective
denervation of the renal sympathetic nerves in addition to
lowering peripheral BP significantly reduces LV mass and
improves diastolic function in patients with resistant hyper-
tension. Extrapolating from drug trials (22,23), the effect on
cardiac remodeling documented in our study suggests a
prognostic benefit of RD in patients with refractory hyper-
tension, which should be evaluated in future trials.
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